Stock code: 300759.SZ

Stock code: 3759.HK

2 0 2 6

Third Quarterly Results

October 2026Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

3Q2026 Revenue & Profit Achieved Solid Growth QoQ & YoY

RMB mm 3Q2026 2Q2026 QoQ 3Q2025 YoY

Revenue 4408 4017 9.7% 3645 20.9%

Net Profit 497 415 19.8% 440 13.1%

Non-IFRS Adjusted Net Profit 587 503 16.8% 471 24.7%

? Both revenue & Non-IFRS adjusted net profit recorded accelerated YoY growth in 3Q2026

compared with 2Q2026

Data are rounded to the nearest million. Above financials are unaudited 31-3Q2026 Financials & Full-Year Outlook

RMB mm 1-3Q2026 1-3Q2025 YoY

Revenue 12003 10086 19.0%

Net Profit 1247 1141 9.3%

Non-IFRS Adjusted Net Profit 1496 1227 22.0%

? New POs: new POs increased by 30%+ YoY

? MNC Customers: revenue from TOP20 Pharmas increased by 52.5% YoY

? Guidance: remain confident in achieving the 2026 revenue growth target of 15–20%

Data are rounded to the nearest million. Above financials are unaudited 41-3Q2026 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

ROW 3%

Clinical Customers from NA

Development Revenue Grew 10.1%

Services 14% Mainland

Customers from EU China

18% North

America

CDMO Laboratory Revenue Grew 30.1%

59%

Services Services Customers from Mainland CN

26% 60% Europe

Revenue Grew 39.1% 20%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New

Customers

China Entities Overseas TOP20 Pharmas 3% TOP20

10% Pharmas

Revenue Grew 22.2% Revenue Grew 52.5%

23%

Overseas Subsidiaries Other Customers

Revenue Declined 3.0% Revenue Grew 11.8%

China Other Repeat

90% Customers

75%

Laboratory Services

RMB mm 3Q2026 2Q2026 QoQ 3Q2025 YoY 1-3Q2026 1-3Q2025 YoY

Revenue 2589 2430 6.6% 2203 17.5% 7222 6278 15.0%

GPM 39.1% 40.2% -1.1pct 42.5% -3.4pct 40.2% 42.6% -2.4pct

? 1–3Q2026: new POs increased by 25%+ YoY. Growth accelerated vs. 1H2026

? GPM declined YoY mainly due to the appreciation of the RMB against the USD during the

Reporting Period

Data are rounded to the nearest million. Above financials are unaudited 6CDMO Services

RMB mm 3Q2026 2Q2026 QoQ 3Q2025 YoY 1-3Q2026 1-3Q2025 YoY

Revenue 1218 1012 20.4% 936 30.1% 3102 2355 31.7%

GPM 31.1% 27.2% 3.9pct 29.5% 1.6pct 27.8% 25.7% 2.1pct

? 1–3Q2026: new POs increased by 40%+ YoY

? As our small molecule CDMO pipeline continues to advance we expect demand for late-stage

clinical and commercial manufacturing to maintain strong growth momentum. In 3Q2026 our

API production facility in Ningbo passed its second on-site inspection by the FDA providing

strong support for our continued production of commercial API for innovative drugs for the U.S.and global markets

Data are rounded to the nearest million. Above financials are unaudited 7Clinical Development Services

RMB mm 3Q2026 2Q2026 QoQ 3Q2025 YoY 1-3Q2026 1-3Q2025 YoY

Revenue 590 568 3.9% 501 18.0% 1659 1440 15.2%

GPM 13.1% 12.1% 1.0pct 10.8% 2.3pct 11.0% 11.8% -0.8pct

? 1–3Q2026: new POs increased by 25%+ YoY

? With continued revenue growth 3Q2026 GPM improved both QoQ & YoY

Data are rounded to the nearest million. Above financials are unaudited 81-3Q2026 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

2.2% 2.2% 2.2% 2.2% 12.7% 12.8% 12.6% 12.9%2.1% 11.9%

2023 2024 2025 1-3Q2025 1-3Q2026 2023 2024 2025 1-3Q2025 1-3Q2026

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

1.0%

0.9% 0.9%

0.8%

3.9% 3.8% 4.1% 3.9% 3.8%

0.1%

2023 2024 2025 1-3Q2025 1-3Q2026 2023 2024 2025 1-3Q2025 1-3Q2026

1. Excluding share-based compensation expenses and one-off reorganization-related expenses recognized in administrative expenses 9

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesScaling Capacity & Supply to Meet Growing Customer Demand

RMB mm

3221

2865

2754

2577 2669

2436

2206

2041

1901 1907

2023 2024 2025 1-3Q2025 1-3Q2026

Net Operating Cash Flow CAPEX

1-3Q2026 Non-IFRS Adjusted Net Profit

RMB mm 1-3Q2026 1-3Q2025

Net Profit 1247 1141

Add:

Share-based Compensation Expenses 48 52

Convertible Bonds Related Expenses 3 -

Foreign Exchange Related Losses 169 31

Amortization of Intangible Assets from Acquisitions 21 2

Realized and Unrealized Gains From Equity Investments (27) 0

One-off Reorganization-related Expenses 34 -

Non-IFRS Adjusted Net Profit 1496 1227

Data are rounded to the nearest million. Above financials are unaudited 112026 Outlook

The evolving healthcare demands and technological innovations will sustain the

development of our industry. Global customer demand continue to demonstrate resilience

while demand from China customers is showing signs of recovery

Continue to develop our end-to-end fully integrated and multiple modalities-capable

service platform commit to the CRDMO business model across the entire drug lifecycle

and deepen the integration of AI & automation across operations to drive sustained growth

Remain confident in achieving the 2026 revenue growth target of 15–20%

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 12

materially from these forward-looking statementsTHANK YOU